Christopher Ogden, Chief Financial Officer at CytomX Therapeutics, Inc. (CTMX), sold 38,646 shares at $6.42 ($248K) on 2026-03-17, disclosed to the SEC on 2026-03-19.
Seasonal sale ($248k) by Chief Financial Officer — this insider has traded CTMX in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.42 | 19,323 | $124K | 50.0% |
| 2 | $6.42 | 19,323 | $124K | 50.0% |
| Total | $6.42 avg | 38,646 | $248K | 100% |
| Filing → |
| CTMX | SELL | 2025-03-20 | $5K | — | Filing → |
| CTMX | SELL | 2024-08-22 | $2K | — | Filing → |
| CTMX | SELL | 2024-03-21 | $6K | — | Filing → |